Remix Therapeutics will go public via reverse merger with Passage Bio, taking its Nasdaq listing alongside a $100M placement as it advances mRNA degrader REM-422 in cancer.
Peter Smith, Remix Therapeutics CEO
June 24, 2026 04:05 PM EDT
FinancingStartupsDeals
Remix to take Nasdaq spot of Passage Bio in reverse merger for mRNA degrader
Kyle LaHucik
The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer Jim…
Caldera-Synlogic and Vidya-Processa ink reverse mergers with Bain-backed placements, advancing a TL1A bispecific and a BTK…
Shares bounded off their 50-day line Monday after inking a deal with Roche for a BTK-degrading drug.
Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III…
Roche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B-cell malignancies.
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends
